Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 14, 2007

View Archived Issues

Vertex Pharmaceuticals reports second quarter 2007 results

Peptech-Evogenix merger approved by shareholders

Novel gene therapy approach for the treatment of juvenile retinoschisis reported

New experimental gene therapy approach for the treatment of retinitis pigmentosa

Anadis plans clinical study of polyclonal antibodies

TaiGen completes patient enrollment for phase II trial of nemonoxacin for CAP

BioForm and Kreussler enter licensing agreement for Aethoxysklerol

Nereus Phamaceuticals will use stock gains to develop cancer therapies

Cytopia achieves primary objectives of phase I trial for i.v. anticancer agent

Calcium and sodium channel blockers patented for use in the treatment of pain

Potential new treatments for obesity and psychiatric disorders patented by Athersys

JAK inhibitors claimed by Vertex for asthma and other conditions

ReAble Therapeutics acquires Iomed

FDA responds to Solvay and Wyeth's NDA for bifeprunox

IND for Genmab antibody submitted by Roche

Patient treatment completed for BioDiem's phase I/II study of BDM-E

ProStrakan and LG Life Sciences sign Sancuso distribution agreement

Sosei completes phase I trial of emergency contraceptive pill NorLevo

PB BioSciences and Dong Wha sign exclusive license agreement for zabofloxacin

Promising clinical results of novel meningococcal group A conjugate vaccine

Bifunctional peptide inhibitor reduces disease progression in animal models of MS

Potential safety issue in phase II clinical study of HCV-796 in hepatitis C

Recent study suggests that cholecystokinin activity in the brain is mediated by endocannabinoids

U.S. launch of AzaSite reported by InSite Vision and Inspire

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 17, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
Viva in vivo! At EHA, in vivo CAR T data continues to impress
BioWorld
Treatment with first-generation CAR T cells regularly sent patients to the intensive care unit. Now, investigators are envisioning a future where CAR T treatment...